International Review of Ophthalmology

Previous Articles     Next Articles

Treatment for adenoid cystic carcinoma of lacrimal gland

Liu Rui, Ma Jianmin   

  1. Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2019-10-10 Online:2019-12-22 Published:2019-12-26
  • Contact: Ma Jianmin, Email: jmma@sina.com
  • Supported by:

    Beijing Natural Science Foundation (7182038)

Abstract:

Adenoid cystic carcinoma of the lacrimal gland is the most common malignant epithelial neoplasm of the lacrimal glands. It develops rapidly, spreads locally and metastases distantly. It has a high recurrence rate and mortality rate. At present, the main clinical treatment methods are surgical resection combined with particle 125I implantation and internal radiotherapy, surgical resection combined with external radiotherapy, surgical resection combined with radiotherapy and chemotherapy, and molecular targeted drug therapy, etc. The above comprehensive treatments has reduced the recurrence rate and prolonged the survival span of patients. At the same time we need to keep in mind the side effects of radiotherapy and chemotherapy.(Int Rev Ophthalmol, 2019, 43: 415-420)